600976.SH
健民集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 27.58
+0.15%Year over year
Reported trailing growth
- Revenue
- -2.2%
- EBITDA
- —
- EBIT
- -11.6%
- EPS
- -8.9%
- Free cash flow
- +73.0%
- Operating cash flow
- +32.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.5%
- EBITDA
- -2.4%
- EBIT
- -4.0%
- Net income
- -4.1%
- EPS
- -4.0%
- Free cash flow
- +5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026